Clene Inc. presented new clinical data at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 meeting. The combined results from the REPAIR-MS study demonstrated that CNM-Au8 improves brain energy metabolism in Multiple Sclerosis (MS) patients.
The Phase 2, open-label study assessed the effects of CNM-Au8 on the bioenergetic improvement of impaired neuronal redox state. The primary endpoint of the study was the change in brain NAD+/NADH ratio, a measure of energetic capacity, from baseline to week 12. Participants included those from REPAIR-MS Cohort 1 (relapsing MS, n=11), REPAIR-MS Cohort 2 (non-active progressive MS, n=15), and REPAIR-PD (n=13) in prespecified analyses across the overall population (total n=39).
CNM-Au8 treatment was found to be safe and well tolerated, with treatment emergent adverse events characterized as transient and predominantly mild-to-moderate in severity. These results reinforce the insight that bioenergetic failure in the brain contributes to neurodegeneration and disease progression in MS, and that CNM-Au8 may help slow disability progression by improving brain energy metabolism.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.